April 25, 2024

In some tests, anti-IL-6 receptor (R) (tocilizumab [Actemra?; Roche Diagnostics], 20 g/mL) and/or IL-6 (40 ng/mL; R&D systems) had been added during differentiation of DC, mainly because described in the CNF impair differentiation and subsequent maturation of DC section differently

In some tests, anti-IL-6 receptor (R) (tocilizumab [Actemra?; Roche Diagnostics], 20 g/mL) and/or IL-6 (40 ng/mL; R&D systems) had been added during differentiation of DC, …